Effect of Early Treatment with Ivermectin among Patients with Covid-19 (TOGETHER platform trial) (2022)

Peer-Reviewed Study · Reis G, Silva EASM, Silva DCM, Thabane L, Milagres AC, Ferreira TS, et al. (TOGETHER investigators) · March 30, 2022

Reis G et al., 2022-03-30: The Brazilian TOGETHER platform trial randomized 3515 outpatients to ivermectin 400 micrograms/kg daily for three days or placebo and found no reduction in hospitalization or prolonged emergency observation.

Treatment with ivermectin did not result in a lower incidence of medical admission to a hospital due to progression of Covid-19 or of prolonged emergency department observation among outpatients with an early diagnosis of Covid-19.

Reis G et al., 2022-03-30: The Brazilian TOGETHER platform trial randomized 3515 outpatients to ivermectin 400 micrograms/kg daily for three days or placebo and found no reduction in hospitalization or prolonged emergency observation. Double-blind, randomized, placebo-controlled adaptive platform trial; 3515 patients randomized, 12 public health clinics in Brazil; symptomatic adults within 7 days of onset with at least one risk factor; ivermectin 400 micrograms/kg once daily for 3 days versus placebo; primary composite outcome medical admission or prolonged emergency observation; relative risk 0.89 (95% Bayesian credible interval 0.69-1.15); per-protocol RR 0.94 (0.67-1.35); no significant effects on secondary outcomes or adverse events. Funded by FastGrants and the Rainwater Charitable Foundation; NCT04727424. No conflicts declared in the PubMed record. Study type: randomized trial.